• KOL
    • Prostate Cancer
    • Philip W Kantoff
    • Philip W Kantoff: Influence Statistics

      Philip W Kantoff

      Philip W Kantoff

      Show email address

      Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115. | Center for Functional Cancer Epigenetics, Dana-Farber Cancer ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Philip W Kantoff:Expert Impact

      Concepts for whichPhilip W Kantoffhas direct influence:Prostate cancer,Androgen deprivation therapy,Abiraterone acetate,Psma adc,Specific antigen,Advanced prostate cancer,Prostatic neoplasms,Prostate specific.

      Philip W Kantoff:KOL impact

      Concepts related to the work of other authors for whichfor which Philip W Kantoff has influence:Prostate cancer,Androgen receptor,Gene expression,Tumor cells,Prostatic neoplasms,Drug delivery,Active surveillance.

      KOL Resume for Philip W Kantoff

      Year
      2022

      Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.

      Memorial Sloan Kettering Cancer Center, NY, NY, Convergent Therapeutics, Inc., Cambridge, MA;

      2021

      Anthony V. D'Amico, MD, PhD, Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA; Wanling Xie, MS, Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA; and Philip W. Kantoff, MD, Department of Medicine, Memorial Sloan Kettering Cancer Institute, New York, NY

      Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

      Convergent Therapeutics Inc., Cambridge, MA 02138, USA

      2020

      Weill Cornell Medical College, New York, NY, USA

      Memorial Sloan Kettering Cancer Center, New York, NY.

      2019

      Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

      Dana‐Farber Cancer Institute, Boston, Massachusetts

      2018

      Memorial Sloan‐Kettering Cancer Center, New York, New York

      Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, 02215, Boston, MA, USA

      Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

      2017

      Dana‐Farber Cancer Institute and Harvard Medical School Lank Center for Genitourinary Oncology Boston Massachusetts

      Weill Cornell Medical College, New York, New York

      Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

      2016

      Nicholas J. Giacalone, Marian Loffredo, and Anthony V. D'Amico, Brigham and Women's Hospital/Dana-Farber Cancer Institute; Nicholas J. Giacalone, Harvard Radiation Oncology Program, Boston, MA; Jing Wu and Ming-Hui Chen, University of Connecticut, Storrs, CT; Andrew Renshaw, Miami Baptist Hospital, Miami, FL; and Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY.

      Department of Medicine, Memorial Sloan Kettering Cancer Center, 600 Third Avenue, New York, NY, USA

      Dana-Farber Cancer Institute, Boston, Massachusetts.

      Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Philip W Kantoff is among the top experts in the world.
      Concept World rank
      metastatic mortality hrs #1
      cvm risk #1
      time mhspc pts #1
      hematocrit adt #1
      development crpc phenotype #1
      hectd2 crpc #1
      bone loss hypogonadal #1
      sipuleucelt longer tfoa #1
      dose premarin #1
      patients eosinophil increase #1
      diseaserelated pain patients #1
      minor alleles rs1318056 #1
      mifepristone disease progression #1
      mineralocorticoid toxicity toxicity #1
      brca2 rb1 #1
      psa pcr #1
      50 blacks #1
      95 normal testosterone #1
      psa failure 108 #1
      recurrence renalcell carcinoma #1
      inhibition csn5 #1
      3 months ast #1
      neoplastic genes predictive #1
      localized risk #1
      local nephrectomy polymorphism #1
      rtpcr tumor cells #1
      taxanes median pfs #1
      taxanebased chemotherapy mitoxantrone #1
      lncrna mir222hg crpc #1
      savings 75 years #1
      mir222hg pca progression #1
      taxane‐based chemotherapy #1
      rs1490311 abl2 #1
      serum crpc patients #1
      greater percentage worse #1
      lgals3 treatment #1
      crpc sses #1
      toxicity therapeutic activity #1
      evidence sufficient #1
      aipc antineoplastic agents #1
      nsllm gm #1
      pca diagnosis comparison #1
      esr2 genes #1
      generation sequencing deletion #1
      tumor yield #1
      taxanes mitoxantrone #1
      diversity ironman registry #1
      mir221 development #1
      nct01133704 #1
      cbt objective attention #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Philip W Kantoff

      KOL-Index: 17668

      OBJECTIVE: Sex steroid hormones are thought to contribute to the growth, differentiation, and progression of prostate cancer. We investigated plasma levels of sex steroid hormones and length of the androgen receptor gene CAG repeat in relation to incident prostate cancer diagnosed in the prostate-specific antigen (PSA) era.

      METHODS: Using a nested case-control design, we included 460 prostate cancer cases diagnosed after providing a blood specimen in 1993 but before February 1998 among ...

      Known for Prostate Cancer | Sex Steroid Hormones | Cag Repeat | Androgen Receptor | Specific Antigen
      KOL-Index: 17208

      BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence.

      OBJECTIVE: To present the results from the APCCC 2019.

      DESIGN, SETTING, AND PARTICIPANTS: Similar to ...

      Known for Advanced Prostate Cancer | Consensus Conference | Management Patients | Molecular Characterisation | Voting Panel
      KOL-Index: 16735

      BACKGROUND: The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (HSPC) either with (M+) or without (M-) metastases.

      METHODS: A cohort of prostate cancer patients was identified from a medical oncology practice treated with ADT for presumed nonlocalized prostate cancer, evaluated the efficacy of ADT using prostate-specific antigen (PSA) time to progression (TTP) and compared ...

      Known for Androgen Deprivation Therapy | Ttp Adt | Prostate Cancer | Neoplasms Hormone | Predictive Factors
      KOL-Index: 15665

      BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics.

      OBJECTIVE: To present the report of APCCC 2017.

      DESIGN, SETTING, AND PARTICIPANTS: Ten important areas of controversy in APC management were identified: high-risk ...

      Known for Prostate Cancer | Consensus Conference | Apccc 2017 | Molecular Characterisation | Multiple Areas
      KOL-Index: 15239

      PURPOSE: Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT.

      PATIENTS AND METHODS: A cohort of 538 patients with prostate cancer treated with ADT was genotyped for SLCO2B1 and SLCO1B3 single nucleotide polymorphisms (SNP). The biologic function of a SLCO2B1 coding SNP in ...

      Known for Prostate Cancer | Androgen Deprivation Therapy | Progression Adt | Slco2b1 Time | Genetic Variants
      KOL-Index: 15205

      OBJECTIVES: Vascular endothelial growth factor (VEGF) is a cytokine that plays an important role in tumor angiogenesis. VEGF is overexpressed in many human cancers, including prostate cancer, but circulating levels of VEGF in patients with prostate cancer have not been reported. In this study, we analyzed plasma concentrations of VEGF in a cohort of patients with prostate cancer and compared them with a normal population.

      METHODS: Twenty-six healthy, cancer-free individuals and 80 ...

      Known for Prostate Cancer | Vegf Patients | Plasma Levels | Endothelial Growth | Localized Disease
      KOL-Index: 14717

      Conventional imaging modalities (CIMs) have limited sensitivity and specificity for detection of metastatic prostate cancer. We examined the potential of a first-in-class radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA), N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-l-cysteine ((18)F-DCFBC), to detect metastatic hormone-naïve (HNPC) and castration-resistant prostate cancer (CRPC).

      METHODS: Seventeen patients were prospectively ...

      Known for Dcfbc Pet | Metastatic Prostate Cancer | Conventional Imaging Modalities | Lesions Cim | Crpc Patients
      KOL-Index: 14664

      CONTEXT: In the United States, 192,000 men were diagnosed as having prostate cancer in 2009, the majority with low-risk, clinically localized disease. Treatment of these cancers is associated with substantial morbidity. Active surveillance is an alternative to initial treatment, but long-term outcomes and effect on quality of life have not been well characterized.

      OBJECTIVE: To examine the quality-of-life benefits and risks of active surveillance compared with initial treatment for men ...

      Known for Active Surveillance | Initial Treatment | Decision Analysis | Prostate Cancer | Quality Life
      KOL-Index: 13798

      BACKGROUND: Whether the genomic rearrangement transmembrane protease, serine 2 (TMPRSS2):v-ets erythroblastosis virus E26 oncogene homolog (ERG) has prognostic value in prostate cancer is unclear.

      METHODS: Among men with prostate cancer in the prospective Physicians' Health and Health Professionals Follow-Up Studies, we identified rearrangement status by immunohistochemical assessment of ERG protein expression. We used Cox models to examine associations of ERG overexpression with ...

      Known for Erg Rearrangement | Prostate Cancer | Lethal Disease | Biochemical Recurrence | Aged Neoplasm
      KOL-Index: 13652

      CONTEXT: Previous animal and human research suggests that testosterone has antinociceptive properties. Castration in male rodents increases pain perception which is reversed by testosterone replacement. Pain perception also improves in hypogonadal men with testosterone therapy. However, it remains unclear whether androgen deprivation therapy (ADT) in men with prostate cancer (PCa) is associated with an increase in pain perception.

      OBJECTIVES: To evaluate the effects of ADT on pain ...

      Known for Pain Perception | Prostate Cancer | Androgen Deprivation Therapy | Adt Pca | Quality Life
      KOL-Index: 13585

      IMPORTANCE: Statin use has been associated with improved prostate cancer outcomes. Dehydroepiandrosterone sulfate (DHEAS) is a precursor of testosterone and a substrate for SLCO2B1, an organic anionic transporter. We previously demonstrated that genetic variants of SLCO2B1 correlated with time to progression (TTP) during receipt of androgen deprivation therapy (ADT). Statins also use SLCO2B1 to enter cells, and thus we hypothesized that they may compete with DHEAS uptake by the tumor ...

      Known for Androgen Deprivation Therapy | Statin Adt | Prostate Cancer | Dheas Uptake | Time Progression
      KOL-Index: 13509

      PURPOSE: Defects in genes in the DNA repair pathways significantly contribute to prostate cancer progression. We hypothesize that overexpression of DNA repair genes may also drive poorer outcomes in prostate cancer. The ribonucleotide reductase small subunit M2 (RRM2) is essential for DNA synthesis and DNA repair by producing dNTPs. It is frequently overexpressed in cancers, but very little is known about its function in prostate cancer.

      EXPERIMENTAL DESIGN: The oncogenic activity of ...

      Known for Prostate Cancer | Dna Repair | Ribonucleotide Reductase | Small Subunit | Overexpression Rrm2
      KOL-Index: 13408

      Importance: Guidelines for cancer genetic testing based on family history may miss clinically actionable genetic changes with established implications for cancer screening or prevention.

      Objective: To determine the proportion and potential clinical implications of inherited variants detected using simultaneous sequencing of the tumor and normal tissue ("tumor-normal sequencing") compared with genetic test results based on current guidelines.

      Design, Setting, and Participants: From ...

      Known for Advanced Cancer | Based Germline | Normal Dna | Clinical Guidelines | Genetic Test
      KOL-Index: 13214

      PURPOSE: Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior platinum-based chemotherapy.

      PATIENTS AND METHODS: The primary objective was to determine whether vandetanib 100 mg plus docetaxel 75 mg/m(2) intravenously every 21 days prolonged ...

      Known for Docetaxel Vandetanib | Pfs Orr | Urothelial Cancer | Progression Disease | Secondary Objectives

      Key People For Prostate Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Peter T Scardino
      prostate cancer active surveillance erectile function
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Johnathan I Jonathan
      prostate cancer gleason score needle biopsy
      #5
      Philip W Kantoff
      prostate cancer psma adc androgen deprivation therapy
      #6
      PATRICK CRAIG Walsh
      prostate cancer specific antigen pathological stage

      Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115. | Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02115. | Department of Medicine, Weill Cornell Medical Center

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.